Investing in our people

Our people bring distinct skills, expertise, ideas and passion to work every day

They are the driving force behind our efforts to deliver on our mission to accelerate innovation for a healthier world.

Learn more

EMPLOYEE VALUE PROPOSITION (EVP)

Connecting with our people

Passion

We make an impact — we are passionate about the work we do and about advancing patient health.

Innovation

We innovate — we are curious, think creatively and bring new ideas to life.

Collaboration

We bring out the best in each other — our different perspectives enable greater impact as we are all working together.

Growth

We are always learning — flexible careers and supportive leaders give us the ability to explore and grow in new ways.

Connecting over 90,000 talented and passionate people across different business units and regions is fundamental to our success. We are focused on building an environment that provides the tools, resources, and support our employees need to collaborate and innovate.

Over the course of 2025, we continued to embed our EVP across all parts of our business.

Brandon Hall Awards

Awards for talent excellence

In 2025, we received external recognition from the Brandon Hall Group for our continued focus on cultivating skills for employee success.

Onboarding & Hybrid Learning. Gold awards for Best New Hire Onboarding Program and Best Hybrid Learning Platform for our global Clinical Research Associate (CRA) training. The program delivers flexible, accessible learning that equips CRAs with the skills needed to support our customers’ research.

Leadership Development. Gold award for Best Leadership Development Program for our Research & Development Solutions General Management Acceleration Program.

Blended Learning. Bronze award for Best Use of Blended Learning for our Manager Excellence Development Program (MEDP), which builds core management skills for new and aspiring people leaders in the clinical business.

Clinical Data Training. Silver award for Best Custom Content for our Medidata Rave Training Program, helping employees confidently use key clinical data platforms essential to trial operations.

Each year, we offer employees a volunteer day: IQVIA Day

Our Employees can use the day to support a local community project, charity or non-profit organization of their choosing. Employees can participate either individually or as part of a group initiative led by IQVIA.

See how we give back

Advancing public health

Creating positive impact for people and the planet through our business

Working with global and local partners to deliver insights, support research and catalyze access to vital treatments for the patients and populations that need them most.

Learn more

Accelerating and optimizing clinical trial delivery

IQVIA adopts a molecule-to-market approach to trial set-up and management. We seek to create efficient and reliable protocol designs that minimize complexity and reduce patient and investigator burden, while optimizing desired outcomes.

Our approach enables us to anticipate changing global regulatory requirements and adapt trial protocols as needed.

Sickle Cell Anemia

We support training at the University of Abuja Teaching Hospital’s Centre of Excellence for Sickle Cell Disease, equipping investigators with the skills needed for clinical research. Through our thought leadership program, we investigated how research into sickle cell disease could help to catalyze greater clinical trials activity across Africa.

Supporting rare disease research

The Bespoke Gene Therapy Consortium (BGTC) is a groundbreaking U.S.-based public–private partnership focused on accelerating development of adeno-associated virus (AAV)-based gene therapies for rare diseases. It aims to enable faster delivery of life-changing treatments to patients with limited or no therapeutic options. IQVIA plays a pivotal role in the initiative as a clinical research organization partner, providing program management and regulatory, operational and strategic drug development support. This includes establishing and managing the BGTC Coordination Center, developing a quality infrastructure, preparing FDA submissions and implementing centralized data platforms. IQVIA also co-authored the BGTC Regulatory Playbook. Through advanced digital operating models and AI-driven analytics, IQVIA is helping streamline trial design and execution, positioning the consortium as a template for future collaborations and accelerating access to innovative therapies for rare disease patients.

Global Public Health

Our global public health activities are central to our mission of accelerating innovation for a healthier world.

We bring a unique set of capabilities that enable us to have a positive impact on some of the world’s biggest health challenges in partnership with governments, healthcare providers, non-governmental organizations and the biopharma industry.

Learn more

Award for patient-centered data collection

IQVIA’s Health Research Space (HRS) helps patients and caregivers participate in studies from wherever they are through a secure platform accessible by phone, tablet or computer. Participants can share their medical records and information on their disease, access educational materials and study support services, and learn about relevant research opportunities.

The platform’s flexibility offers a convenient way to share information safely, reducing the need for in-person appointments and supporting ongoing engagement for multi-year studies.

In 2025, HRS received the Medtech Breakthrough Award for Best Mobile App for Patient Engagement, which recognizes solutions making meaningful progress and improving patient care.

Learn more about HRS

AI delivers tangible trial benefits

IQVIA is expanding the use of AI to accelerate clinical development and improve access to trials. For more than a decade, we have used advanced technology to identify high performing sites and support more efficient recruitment. Today we are evolving these capabilities with AI agents that work alongside our experts to enhance operational efficiency and reduce burden across the trial process.

By embedding agentic AI into targeted workflows, we streamline steps across clinical development processes and milestones. These agents do not replace clinical judgment; instead, they augment experts to expedite processes and surface insights so teams can focus on the scientific and strategic decisions needed for efficient trial execution that truly influence patient outcomes.

We continue to explore where AI can meaningfully improve clinical research, from discovery through trial execution. For example, AI-driven insights can help identify new opportunities for development in areas that have historically been challenging. This could be particularly valuable for diseases affecting small patient populations.

Through Agentic AI, IQVIA is enhancing speed, scale, precision, and trust across clinical development — helping sponsors run higher quality trials and ultimately bring new therapies to patients faster.

Driving environmental impact

We are committed to reducing our impact on the environment

We focus on the areas where we have the greatest opportunity to effect positive change.

Learn more

Reducing our environmental impact

IQVIA’s environmental footprint is primarily linked to our supply chain and the operations of IQVIA Laboratories, along with the energy and resources consumed across our broader operations. We are committed to reducing our environmental impact both within our own operations and throughout our value chain. By collaborating with suppliers and building partnerships with our customers, we aim to drive collective progress towards our environmental goals.

Learn more

Sustainability in our laboratories

IQVIA is proud of the research and innovation taking place in our laboratories. As we continue to explore new scientific possibilities, we are also focused on lowering the environmental footprint of our operations, making sustainability a key part of how we innovate. My Green Lab (MGL) is a global initiative encouraging more environmentally sustainable practices in scientific research. It is the healthcare industry’s most widely recognized laboratory sustainability certification program — recommended by the U.S. Environmental Protection Agency and endorsed by the Race to Zero campaign, which is backed by the United Nations. MGL supports a collaborative and holistic approach to reducing impacts, and certifies participating laboratories based on progress.

The certification process takes 6-8 months, involving a baseline assessment, working with the MGL team to investigate areas for improvement and implement policies, actions, and trainings. Laboratories must reevaluate their processes to apply for recertification every two years.

Through our dedication to the MGL initiative, IQVIA is making consistent progress in lowering the environmental footprint of our laboratories. As of 2025, 100% of our laboratories are MGL-certified and over 150 IQVIA employees are trained MGL ambassadors, committed to championing progress.

Waste reduction: Re-engineering our clinical trial test kits services

Re-engineering our clinical trial test kit services is one of our biggest opportunities to reduce waste. We are reducing single-use plastic packaging and optional items from our test kits, such as single-use needles and pipettes.

Last year, we removed almost 3 metric tons of single-use plastic outer packaging for clinical trial test kits from our supply chain at our Edinburgh and Marietta central labs.
We are transitioning to recycled cardboard boxes, replacing bleached virgin cardboard within our kit supply chain.
We have identified further opportunities to reuse dry ice in frozen shipments, expanded polystyrene and gel packs. We continue to look for more sustainable options throughout our clinical trial test kit service.

To reduce unnecessary waste of our test kits, we are using our advanced analytics to improve trial materials management. This aims to match supply to demand more precisely and prevent unnecessary surplus of kits.

We have been working in partnership with clinical trial sites to advise, educate and guide positive behaviors with regards to kit ordering, with the aim to reduce the risk of waste in our supply chain in the future. We partner with our customers to reduce waste rates of kits through the advocacy of external initiatives such as Kits4Life. Read more about our operational waste reduction efforts on page 77 in our report.

Honors

External awards and recognition

Through our relentless focus on the delivery of our mission we continue to be recognized as a leader across the healthcare industry.

2025 Sustainability Report

Sustainability is central to our mission of accelerating innovation for a healthier world. Every day, we collaborate with customers and partners to improve health outcomes and increase our positive impact.

READ OUR REPORT

Supporting documents

As part of our continued commitment to transparency, IQVIA has made its most recent EEO-1 Component 1 report publicly available in the link below. The EEO-1 Component 1 report is a mandatory annual data collection by the U.S. Equal Employment Opportunity Commission that requires all private sector employers with 100 or more employees, and federal contractors with 50 or more employees meeting certain criteria, to submit demographic workforce data, including data by race/ethnicity, sex and job categories.

EEO-1 2024 Consolidated Report

Our approach to sustainability

Investing in our people

Our people bring distinct skills, expertise, ideas and passion to work every day

EMPLOYEE VALUE PROPOSITION (EVP)​

Connecting with our people​

Passion​

Innovation

Collaboration

Growth

Brandon Hall Awards

Awards for talent excellence​

Each year, we offer employees a volunteer day: IQVIA Day

Advancing public health

Creating positive impact for people and the planet through our business

Accelerating and optimizing clinical trial delivery

Sickle Cell Anemia

Supporting rare disease research​

Global Public Health

Award for patient-centered data collection

AI delivers tangible trial benefits

Driving environmental impact

We are committed to reducing our impact on the environment

Reducing our environmental impact​

Sustainability in our laboratories

Waste reduction: Re-engineering our clinical trial test kits services

Honors

External awards and recognition

2025 Sustainability Report

Supporting documents

EMPLOYEE VALUE PROPOSITION (EVP)

Connecting with our people

Passion

Awards for talent excellence

Supporting rare disease research

Reducing our environmental impact